Replies to post #198011 on Biotech Values

[DewDiligence]

ABBV—10% CR [for Venetoclax] is a failure. Imbruvica probably has that much. So, it's a success as far as it's approvable based on this study, but how will it compete against Imbruvica?

Good question. Moreover, Venetoclax’s SAEs were somewhat troubling.

[DewDiligence]

ABBV/Roche—Venetoclax NDA in second-line CLL accepted by FDA with priority review; corresponding MAA validated by EMA:

http://finance.yahoo.com/news/u-european-regulators-accept-applications-133000651.html

The PDUFA date should be on or about 7/11/16.